BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon

Michele Stanchina, Zoe McKinnell, Jae H. Park, Eytan M. Stein, Sheng F. Cai, Justin Taylor

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Article number100211
JournalLeukemia Research Reports
Volume14
DOIs
StatePublished - 2020

Keywords

  • Bcr-abl
  • Chronic myeloid leukemia
  • Dasatinib
  • Imatinib
  • Nilotinib
  • Ponatinib

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this